CD19 and neoplasm: Multiple scRNA-seq studies have found mechanisms of non-response and relapse after CD19 CAR therapy, which can be categorized as a result of immune escape by tumor cells (i.e., loss of the target antigen CD19) or suboptimal CAR T cell function.